Literature DB >> 32253709

Retrospective review of D-dimer testing for venous thrombosis recurrence risk stratification: is this a useful test in the real world?

Julie Wang1, Mark Tacey2, Prahlad Ho2,3,4.   

Abstract

Predicting the risk of recurrence after venous thromboembolism (VTE) remains an important clinical challenge. Post-anticoagulation cessation D-dimer has previously been shown to be associated with increased VTE recurrence in unprovoked major VTE, however this is not routinely used clinically and has not been validated in provoked VTE and isolated distal DVT (IDDVT). We aimed to retrospectively evaluate this practice in the real-world setting including examining its use in provoked VTE and IDDVT. Consecutive patients diagnosed with DVT or PE between January 2013 and December 2016 were retrospectively evaluated. Clinical features, VTE risk factors, recurrence and bleeding rates were evaluated for patients with normal and abnormal post-anticoagulation D-dimer, as well as those patients who did not undergo D-dimer testing. Patients with active malignancy, superficial vein thrombosis and inadequate follow-up were excluded. Of the 1033 patients with a diagnosis of VTE in the study period, 173 were included in the "D-dimer tested" group, and 254 in the "D-dimer un-tested" comparison group. Abnormal post-anticoagulation D-dimer was significantly associated with VTE recurrence (HR 5.96, 95% CI 2.15-14.57, p < 0.001). Abnormal D-dimer was also associated with high risk of VTE recurrence in travel-provoked VTE (67.61 events per 100 patient-years), and unprovoked IDDVT (HR 14.37, 95% CI 1.75-117.83, p = 0.013). Males with abnormal post-anticoagulation D-dimer were associated with the highest risk of VTE recurrence (HR 12.95, 95% CI 2.78-60.20, p = 0.001). Patients with unprovoked proximal DVT and/or PE who underwent D-dimer testing had a lower VTE recurrence rate compared to those who did not have D-dimer testing (HR 0.28, 95% CI 0.10-0.80, p = 0.017). We confirm the utility of post-anticoagulation cessation D-dimer testing to stratify VTE recurrence risk in the real-world setting, including potentially a role of this assay for predicting subsequent VTE in travel-provoked VTE and unprovoked IDDVT.

Entities:  

Keywords:  D-dimer; Post-anticoagulation risk stratification; Recurrence; Venous thromboembolism

Mesh:

Substances:

Year:  2020        PMID: 32253709     DOI: 10.1007/s11239-020-02101-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  32 in total

1.  D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

Authors:  Clive Kearon; Frederick A Spencer; Denis O'Keeffe; Sameer Parpia; Sam Schulman; Trevor Baglin; Scott M Stevens; Scott Kaatz; Kenneth A Bauer; James D Douketis; Steven R Lentz; Craig M Kessler; Stephan Moll; Jean M Connors; Jeffrey S Ginsberg; Luciana Spadafora; Jim A Julian
Journal:  Ann Intern Med       Date:  2015-01-06       Impact factor: 25.391

2.  Real-world direct oral anticoagulant experience in atrial fibrillation: falls risk and low dose anticoagulation are predictive of both bleeding and stroke risk.

Authors:  Rowena Brook; Oranut Aswapanyawongse; Mark Tacey; Tanun Kitipornchai; Prahlad Ho; Hui Y Lim
Journal:  Intern Med J       Date:  2020-11       Impact factor: 2.048

3.  D-dimer testing to determine the duration of anticoagulation therapy.

Authors:  Gualtiero Palareti; Benilde Cosmi; Cristina Legnani; Alberto Tosetto; Carlotta Brusi; Alfonso Iorio; Vittorio Pengo; Angelo Ghirarduzzi; Corrado Pattacini; Sophie Testa; Anthonie W A Lensing; Armando Tripodi
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

Review 4.  Management of distal deep vein thrombosis.

Authors:  Helia Robert-Ebadi; Marc Righini
Journal:  Thromb Res       Date:  2016-11-10       Impact factor: 3.944

Review 5.  Guidelines on travel-related venous thrombosis.

Authors:  Henry G Watson; Trevor P Baglin
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

Review 6.  Natural history of venous thromboembolism.

Authors:  Clive Kearon
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

7.  Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants--a prospective study.

Authors:  G Palareti; C Legnani; G Guazzaloca; M Frascaro; F Grauso; F De Rosa; G Fortunato; S Coccheri
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

8.  Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors.

Authors:  T Baglin; C R Palmer; R Luddington; C Baglin
Journal:  J Thromb Haemost       Date:  2008-01-08       Impact factor: 5.824

Review 9.  D-dimer antigen: current concepts and future prospects.

Authors:  Soheir S Adam; Nigel S Key; Charles S Greenberg
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

10.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Authors:  Gary E Raskob; Nick van Es; Peter Verhamme; Marc Carrier; Marcello Di Nisio; David Garcia; Michael A Grosso; Ajay K Kakkar; Michael J Kovacs; Michele F Mercuri; Guy Meyer; Annelise Segers; Minggao Shi; Tzu-Fei Wang; Erik Yeo; George Zhang; Jeffrey I Zwicker; Jeffrey I Weitz; Harry R Büller
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.